Marina Lanciotti
Research Subjects
Marina Lanciotti has a total of 375 co-authors. Here are the top co-authors by number of shared publications:
Carlo Dufour
36Hematology Unit, IRCCS G. Gaslini Children's Hospital, Genoa, Italy
18 shared publications- Francesca Fioredda
Hematology Unit IRCCS Istituto Giannina Gaslini Genoa Italy
9 shared publications - Mirco Ponzoni
Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
9 shared publications - Johanna Svahn
Clinical and Experimental Hematology Unit, G. Gaslini Children's Hospital, Genoa, Italy
8 shared publications - Piero Farruggia
Pediatric Hematology and Oncology Unit, Pediatric Department, ARNAS Civico, Di Cristina and Benfratelli Hospitals
8 shared publications P. Cornaglia-Ferraris
G. Gaslini Children's Hospital
7 shared publications
Latest Publications
- Open Access
- 18 November 2025
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 45 (1) , 165
Neurological Phenotypes of SOCS1 Haploinsufficiency: Insights from Functional and Histological Investigations
Suppressor of cytokine signaling 1 (SOCS1) haploinsufficiency is a recently described inborn error of immunity characterized by autoimmunity, inflammation, lymphoproliferation, and increased infection susceptibility. SOCS1, a negative regulator of cytokine signaling via the JAK/STAT pathway, explains the condition’s broad phenotypic variability. Single nucleotide polymorphisms in SOCS1 have been linked to multiple sclerosis (MS), and SOCS1 mimetics have shown efficacy in MS animal models. However, neurological involvement has not been previously reported in patients with SOCS1 insufficiency. We describe a family with a heterozygous SOCS1 variant, highlighting neurological manifestations such as MS, autoimmune encephalitis, and recurrent complex regional pain syndrome as novel features. Next-Generation Sequencing and segregation analysis were performed on PBMCs from patients and healthy donors. Functional studies included luciferase reporter assays in HeLa cells expressing the SOCS1 mutant, flow cytometry for phenotypic analysis, and gene expression profiling of the type-I interferon (IFN) signature. Intraepidermal nerve fiber density was evaluated via immunohistochemistry on skin biopsy. Genetic analysis confirmed the variant’s inheritance. Transfected cells carrying the SOCS1 variant showed increased STAT1 transcriptional activity after IFN-γ stimulation. Elevated STAT5 phosphorylation and T-cell proliferation were observed in response to IL-2. Peripheral blood revealed an elevated IFN signature during relapse. Skin biopsy showed reduced intraepidermal nerve fiber density. This report expands the clinical spectrum of SOCS1-related disorders to include neurological symptoms, emphasizing SOCS1’s critical role in regulating inflammation in the central and peripheral nervous systems.
- 18 November 2025
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 45 (1) , 165
Open AccessNeurological Phenotypes of SOCS1 Haploinsufficiency: Insights from Functional and Histological Investigations
Suppressor of cytokine signaling 1 (SOCS1) haploinsufficiency is a recently described inborn error of immunity characterized by autoimmunity, inflammation, lymphoproliferation, and increased infection susceptibility. SOCS1, a negative regulator of cytokine signaling via the JAK/STAT pathway, explains the condition’s broad phenotypic variability. Single nucleotide polymorphisms in SOCS1 have been linked to multiple sclerosis (MS), and SOCS1 mimetics have shown efficacy in MS animal models. However, neurological involvement has not been previously reported in patients with SOCS1 insufficiency. We describe a family with a heterozygous SOCS1 variant, highlighting neurological manifestations such as MS, autoimmune encephalitis, and recurrent complex regional pain syndrome as novel features. Next-Generation Sequencing and segregation analysis were performed on PBMCs from patients and healthy donors. Functional studies included luciferase reporter assays in HeLa cells expressing the SOCS1 mutant, flow cytometry for phenotypic analysis, and gene expression profiling of the type-I interferon (IFN) signature. Intraepidermal nerve fiber density was evaluated via immunohistochemistry on skin biopsy. Genetic analysis confirmed the variant’s inheritance. Transfected cells carrying the SOCS1 variant showed increased STAT1 transcriptional activity after IFN-γ stimulation. Elevated STAT5 phosphorylation and T-cell proliferation were observed in response to IL-2. Peripheral blood revealed an elevated IFN signature during relapse. Skin biopsy showed reduced intraepidermal nerve fiber density. This report expands the clinical spectrum of SOCS1-related disorders to include neurological symptoms, emphasizing SOCS1’s critical role in regulating inflammation in the central and peripheral nervous systems.
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 72-73
Clinical and immunological prophyle of long lasting and late onset neutropenia: beyond primary autoimmune and idiopathic neutropenia
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 72-73
Clinical and immunological prophyle of long lasting and late onset neutropenia: beyond primary autoimmune and idiopathic neutropenia
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 8331-8333
Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry
INTRODUCTION Severe Congenital Neutropenia includes several disorders characterized by absolute neutrophil count depletion appearing early in life, high propens
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 8331-8333
Open AccessPhenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry
INTRODUCTION Severe Congenital Neutropenia includes several disorders characterized by absolute neutrophil count depletion appearing early in life, high propens
- Open Access
- 18 November 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (22) , 5644-5649
Late-onset and long-lasting autoimmune neutropenia: an analysis from the Italian Neutropenia Registry
Primary autoimmune neutropenia (pAN) is typified by onset in early infancy and a mild/moderate phenotype that resolves within 3 years of diagnosis. In contrast, secondary AN is classically an adult disease associated with malignancy, autoimmunity, immunodeficiency, viral infection, or drugs. This study describes a cohort of 79 children from the Italian Registry who, although resembling pAN, did not fully match the criteria for pAN because neutropenia either appeared after age 5 years (LO-Np) or lasted longer than 3 years (LL-Np). These 2 categories compared with classical pAN showed a far inferior rate of resolution (P < .001), lower severity of neutropenia (P = .03), leukopenia (P < .001), lymphopenia (P < .001) with low B+ (P = .001), increased need of granulocyte colony-stimulating factor (P = .04), and increased frequency of autoimmunity over the disease course (P < .001). A paired comparison between LO-Np and LL-Np suggested that LO-Np had a lower rate of resolution (P < .001) and lower white blood cell (P < .001) and lymphocyte (P < .001) values, higher occurrence of apthae (P = .008), and a stronger association with autoimmune diseases/markers (P = .001) than LL-Np, thus suggesting a more pronounced autoimmune signature for LO-Np. A next-generation sequencing panel applied in a small subgroup of LO-Np and LL-Np patients identified variants related to immune dysregulations. Overall, these findings indicate that there are important differences among pAN LL-Np and LO-Np. Forms rising after 3 years of age, with low tendency to resolution, require tight monitoring and extensive immune investigations aimed to early identify underlying immunologic disease.
- 18 November 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (22) , 5644-5649
Open AccessLate-onset and long-lasting autoimmune neutropenia: an analysis from the Italian Neutropenia Registry
Primary autoimmune neutropenia (pAN) is typified by onset in early infancy and a mild/moderate phenotype that resolves within 3 years of diagnosis. In contrast, secondary AN is classically an adult disease associated with malignancy, autoimmunity, immunodeficiency, viral infection, or drugs. This study describes a cohort of 79 children from the Italian Registry who, although resembling pAN, did not fully match the criteria for pAN because neutropenia either appeared after age 5 years (LO-Np) or lasted longer than 3 years (LL-Np). These 2 categories compared with classical pAN showed a far inferior rate of resolution (P < .001), lower severity of neutropenia (P = .03), leukopenia (P < .001), lymphopenia (P < .001) with low B+ (P = .001), increased need of granulocyte colony-stimulating factor (P = .04), and increased frequency of autoimmunity over the disease course (P < .001). A paired comparison between LO-Np and LL-Np suggested that LO-Np had a lower rate of resolution (P < .001) and lower white blood cell (P < .001) and lymphocyte (P < .001) values, higher occurrence of apthae (P = .008), and a stronger association with autoimmune diseases/markers (P = .001) than LL-Np, thus suggesting a more pronounced autoimmune signature for LO-Np. A next-generation sequencing panel applied in a small subgroup of LO-Np and LL-Np patients identified variants related to immune dysregulations. Overall, these findings indicate that there are important differences among pAN LL-Np and LO-Np. Forms rising after 3 years of age, with low tendency to resolution, require tight monitoring and extensive immune investigations aimed to early identify underlying immunologic disease.
- Open Access
- 12 March 2018
- Published by Wiley in British Journal of Haematology
- Vol. 184 (5) , 861-864
Clinical features and therapeutic challenges of cytopenias belonging to alps and alps‐related (ARS) phenotype
- 12 March 2018
- Published by Wiley in British Journal of Haematology
- Vol. 184 (5) , 861-864
Open AccessClinical features and therapeutic challenges of cytopenias belonging to alps and alps‐related (ARS) phenotype
- Open Access
- 6 October 2017
- Published by MDPI AG in Pediatric Reports
- Vol. 9 (3) , 47-49
Clinical Heterogeneity in a Family with DKC1 Mutation, Dyskeratosis Congenita and Hoyeraal-Hreidarsson Syndrome in First Cousins
Dyskeratosis congenita (DC) is an inherited bone marrow failure disorder characterized by mucocutaneous features (skin pigmentation, nail dystrophy and oral leukoplakia), pulmonary fibrosis, hematologic and solid malignancies. Its severe form, recognized as Hoyeraal-Hreidarsson syndrome (HHS), also includes cerebellar hypoplasia, microcephaly, developmental delay and prenatal growth retardation. In literature phenotypic variability among DC patients sharing the same mutation is wellknown. To our knowledge this report describes for the first time a family of DC patients, characterized by a member with features of classic DC and another one with some features of HHS, both with the same mutation in DKC1. Our family confirms again that one mutation can be associated with different phenotypes and different hematological manifestations. It’s possible to speculate that there are likely to be patients who do not clinically fit neatly into either classical DC or HHS, but whose clinical features are due to mutations in DKC1 or in genes responsible for autosomal DC/HHS.
- 6 October 2017
- Published by MDPI AG in Pediatric Reports
- Vol. 9 (3) , 47-49
Open AccessClinical Heterogeneity in a Family with DKC1 Mutation, Dyskeratosis Congenita and Hoyeraal-Hreidarsson Syndrome in First Cousins
Dyskeratosis congenita (DC) is an inherited bone marrow failure disorder characterized by mucocutaneous features (skin pigmentation, nail dystrophy and oral leukoplakia), pulmonary fibrosis, hematologic and solid malignancies. Its severe form, recognized as Hoyeraal-Hreidarsson syndrome (HHS), also includes cerebellar hypoplasia, microcephaly, developmental delay and prenatal growth retardation. In literature phenotypic variability among DC patients sharing the same mutation is wellknown. To our knowledge this report describes for the first time a family of DC patients, characterized by a member with features of classic DC and another one with some features of HHS, both with the same mutation in DKC1. Our family confirms again that one mutation can be associated with different phenotypes and different hematological manifestations. It’s possible to speculate that there are likely to be patients who do not clinically fit neatly into either classical DC or HHS, but whose clinical features are due to mutations in DKC1 or in genes responsible for autosomal DC/HHS.
- 27 October 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (17) , 2178-2181
Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data
To the editor: Severe congenital neutropenia (SCN) is a rare disease characterized by a severe defect in neutrophil production and by high risks of lethal infection.[1][1],[2][2] Lifetime treatment with granulocyte colony-stimulating factor (G-CSF) is indicated in patients responding to standard
- 27 October 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (17) , 2178-2181
Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data
To the editor: Severe congenital neutropenia (SCN) is a rare disease characterized by a severe defect in neutrophil production and by high risks of lethal infection.[1][1],[2][2] Lifetime treatment with granulocyte colony-stimulating factor (G-CSF) is indicated in patients responding to standard
- 1 August 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 55 (2) , 187-188
Ser245Tyr TINF2 mutation in a long-term survivor after a second myeloablative SCT following late graft failure for Aplastic Anaemia
- 1 August 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 55 (2) , 187-188
Ser245Tyr TINF2 mutation in a long-term survivor after a second myeloablative SCT following late graft failure for Aplastic Anaemia
- Open Access
- 17 June 2015
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (18) , 5093-5108
AluY-mediated germline deletion, duplication and somatic stem cell reversion inUBE2Tdefines a new subtype of Fanconi anemia
Fanconi anemia (FA) is a rare inherited disorder clinically characterized by congenital malformations, progressive bone marrow failure and cancer susceptibility. At the cellular level, FA is associated with hypersensitivity to DNA-crosslinking genotoxins. Eight of 17 known FA genes assemble the FA E3 ligase complex, which catalyzes monoubiquitination of FANCD2 and is essential for replicative DNA crosslink repair. Here, we identify the first FA patient with biallelic germline mutations in the ubiquitin E2 conjugase UBE2T. Both mutations were aluY-mediated: a paternal deletion and maternal duplication of exons 2–6. These loss-of-function mutations in UBE2T induced a cellular phenotype similar to biallelic defects in early FA genes with the absence of FANCD2 monoubiquitination. The maternal duplication produced a mutant mRNA that could encode a functional protein but was degraded by nonsense-mediated mRNA decay. In the patient's hematopoietic stem cells, the maternal allele with the duplication of exons 2–6 spontaneously reverted to a wild-type allele by monoallelic recombination at the duplicated aluY repeat, thereby preventing bone marrow failure. Analysis of germline DNA of 814 normal individuals and 850 breast cancer patients for deletion or duplication of UBE2T exons 2–6 identified the deletion in only two controls, suggesting aluY-mediated recombinations within the UBE2T locus are rare and not associated with an increased breast cancer risk. Finally, a loss-of-function germline mutation in UBE2T was detected in a high-risk breast cancer patient with wild-type BRCA1/2. Cumulatively, we identified UBE2T as a bona fide FA gene (FANCT) that also may be a rare cancer susceptibility gene.
- 17 June 2015
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (18) , 5093-5108
Open AccessAluY-mediated germline deletion, duplication and somatic stem cell reversion inUBE2Tdefines a new subtype of Fanconi anemia
Fanconi anemia (FA) is a rare inherited disorder clinically characterized by congenital malformations, progressive bone marrow failure and cancer susceptibility. At the cellular level, FA is associated with hypersensitivity to DNA-crosslinking genotoxins. Eight of 17 known FA genes assemble the FA E3 ligase complex, which catalyzes monoubiquitination of FANCD2 and is essential for replicative DNA crosslink repair. Here, we identify the first FA patient with biallelic germline mutations in the ubiquitin E2 conjugase UBE2T. Both mutations were aluY-mediated: a paternal deletion and maternal duplication of exons 2–6. These loss-of-function mutations in UBE2T induced a cellular phenotype similar to biallelic defects in early FA genes with the absence of FANCD2 monoubiquitination. The maternal duplication produced a mutant mRNA that could encode a functional protein but was degraded by nonsense-mediated mRNA decay. In the patient's hematopoietic stem cells, the maternal allele with the duplication of exons 2–6 spontaneously reverted to a wild-type allele by monoallelic recombination at the duplicated aluY repeat, thereby preventing bone marrow failure. Analysis of germline DNA of 814 normal individuals and 850 breast cancer patients for deletion or duplication of UBE2T exons 2–6 identified the deletion in only two controls, suggesting aluY-mediated recombinations within the UBE2T locus are rare and not associated with an increased breast cancer risk. Finally, a loss-of-function germline mutation in UBE2T was detected in a high-risk breast cancer patient with wild-type BRCA1/2. Cumulatively, we identified UBE2T as a bona fide FA gene (FANCT) that also may be a rare cancer susceptibility gene.